The University of Minnesota recently published significant results involving a breakthrough trial which demonstrated improved survival rates for dogs diagnosed with hemangiosarcoma (HSA). (See the article in Molecular Cancer Therapeutics).
Canine HSA is a vascular cancer (involving blood vessels) and is very similar to angiosarcoma in humans. Both cancers are aggressive and spread before diagnosis, typically with devastating results.
The study used the UMN-developed drug eBAT which simultaneously targets the tumor and its vascular system. Results showed a substantial six-month survival rate for the 23 dogs in the study, with five dogs surviving beyond 450 days. The study also determined a dose of eBAT that allowed effective treatment with substantially fewer side effects.
The researchers believe the study’s positive results, along with the similarities between HSA and angiosarcoma in humans, make a strong case for potential clinical trials for human cancer patients.
Rein in Sarcoma was one of many funding sources for this research. See the announcement of 2017 RIS sarcoma research grants to the University of Minnesota.
Join us for the 2017 Party in the Park Kickoff Meeting!
All who are interested in volunteering are encouraged to attend the 2017 Party in the Park Kickoff meeting and celebration on Tuesday, March 14. We have a great evening planned:
For the first time ever, we are holding this meeting at Summit Brewing Company in St. Paul. The Signature Cafe food truck will be available from 5:30 p.m. – 7:00 p.m., along with a free beer or root beer. The meeting will begin at 7:00 p.m. There is also a free brewery tour at 6:00 p.m. So, be sure to sign up for a fun and productive evening! For more info and to RSVP, click here.
Silent Auction Committee Dinner Meeting – March 29
One of the specific sub-committees already getting in full gear is the Auction Committee. Chair, Jason Patalonis will be hosting a dinner meeting on Wednesday, March 29. For more information.
Opportunity for Osteosarcoma patients and families
The University of Minnesota Masonic Cancer Center recently established the Biology of Osteosarcoma (BOOST) Registry and Biobank which offers a single location where every patient with osteosarcoma and their relatives can participate in research. The hope is that by gathering information on a very large number of osteosarcoma patients and their families from all over the world, researchers can gain a better understanding of osteosarcoma incidence and survival which may lead to the ability to predict who is susceptible, detect tumors when they are small and eventually a cure.
The BOOST registry and ongoing University of Minnesota osteosarcoma research is made possible in part through the Zach Sobiech Osteosarcoma Fund of the Children's Cancer Research Fund, as well as the Rein in Sarcoma Foundation.